Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.
Off-label uses include:
1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.
Pfizer Investigational Site, Seoul, Korea, Republic of
Stanford University Medical Center, Palo Alto, California, United States
Piedmont Atlanta Hospital, Atlanta, Georgia, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Samsung Medical Center, Seoul, Korea, Republic of
Angers University Hospital, Angers, France
Anhui Provincial Hospital, Hefei, Anhui, China
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Anhui Provincial Hospital, Hefei, Anhui, China
Yantai Yuhuangding Hospital, Yantai, Shangdong, China
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
Queen Mary Hospital, Hong Kong, Hong Kong
Prince of Wales Hospital, Randwick, New South Wales, Australia
Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
Health Sciences North, Sudbury, Ontario, Canada
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.